BMRA

Business Context and Reporting Period

Company: Biomerica, Inc. (BMRA)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended November 30, 2024
Business Overview: Biomerica is a global biomedical technology company developing diagnostic and therapeutic products, primarily focusing on gastrointestinal diseases (e.g., inFoods® IBS) and point-of-care testing. The company operates as a single segment with manufacturing facilities in the U.S. and Mexico.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 4% ($69,000) for the three months and 5% ($163,000) for the six months compared to the prior year periods. Growth was driven by increased contract manufacturing billings and sales in the Middle East, partially offset by a decline in clinical lab sales.
• Cost Reductions: Operating expenses decreased significantly due to a workforce reduction (RIF) of nearly 15% executed in July 2024.
  • SG&A: Decreased 23% ($348,000) for the quarter and 6% ($163,000) for the six months.
  • R&D: Decreased 38% ($155,000) for the quarter and 37% ($329,000) for the six months.
• Margin Improvement: Gross margin for the three months improved to 26.7% from 20.7% in the prior year, aided by reduced labor costs. However, the six-month gross margin decreased slightly to 21.0% from 22.6% due to higher costs associated with contract manufacturing volume.
• Cash Position: Cash and cash equivalents declined from $4,170,000 at May 31, 2024, to $2,372,000 at November 30, 2024, reflecting a net cash outflow from operations of $2,135,000 for the six-month period.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. Current cash reserves are deemed insufficient to meet operating requirements for the next twelve months without additional financing.
• Financing Activities: The company raised $567,000 in net proceeds during the six months ended November 30, 2024, through an At-The-Market (ATM) offering. The company has a shelf registration allowing for up to $20,000,000 in equity issuance, though capital raised is constrained by low stock trading volume and price.
• Strategic Initiatives: The company is pursuing cost-cutting measures, selling non-core assets, and seeking strategic alternatives to extend its cash runway. Product launches for inFoods® IBS and hp+detect™ are ongoing but have been slower than expected.
• Risks: Key risks include the need for additional capital, dependence on a small number of key customers (four customers accounted for 58% of sales in the quarter), and the ability to retain key employees post-workforce reduction.
• Executive Compensation: New employment agreements were entered into in January 2025 for the CEO and Executive Vice Chairman, providing for severance payments equal to twelve months of base salary in the event of a change in control.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $2.37M cash balance against the stated burn rate and the timeline for securing additional financing.
• Customer Concentration: Assess the risk associated with four key customers representing 58% of quarterly sales.
• ATM Offering Viability: Monitor stock trading volume and price, as these directly limit the company's ability to raise capital under the current ATM program.
• Product Commercialization: Track the adoption rates and revenue contribution of the inFoods® IBS and hp+detect™ products to determine if they can offset the decline in clinical lab sales.
• Cost Structure: Confirm that the 15% workforce reduction has resulted in sustainable long-term operating expense reductions.